Shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) have been given an average rating of “Hold” by the fourteen brokerages that are presently covering the firm. Two analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $25.35.

Several research analysts have weighed in on the company. Vetr upgraded Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and set a $12.60 target price on the stock in a research note on Monday, August 8th. WallachBeth Capital downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 target price on the stock. in a research note on Tuesday, July 5th. Citigroup Inc. reiterated a “buy” rating and issued a $22.00 target price (down from $36.00) on shares of Esperion Therapeutics in a research note on Wednesday, June 29th. Lake Street Capital lowered their target price on Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, June 29th. Finally, Zacks Investment Research downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 30th.

In other news, Director Mark E. Mcgovern acquired 5,000 shares of Esperion Therapeutics stock in a transaction that occurred on Wednesday, July 6th. The stock was purchased at an average cost of $10.00 per share, with a total value of $50,000.00. Following the completion of the acquisition, the director now owns 600 shares in the company, valued at approximately $6,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 35.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System boosted its position in Esperion Therapeutics by 8.1% in the second quarter. California State Teachers Retirement System now owns 30,016 shares of the biopharmaceutical company’s stock worth $297,000 after buying an additional 2,251 shares during the period. FNY Managed Accounts LLC bought a new position in Esperion Therapeutics during the second quarter worth $1,976,000. Bank of Montreal Can bought a new position in Esperion Therapeutics during the second quarter worth $215,000. Fox Run Management L.L.C. bought a new position in Esperion Therapeutics during the second quarter worth $289,000. Finally, Squarepoint Ops LLC bought a new position in Esperion Therapeutics during the first quarter worth $703,000. 65.22% of the stock is owned by institutional investors.

Esperion Therapeutics (NASDAQ:ESPR) opened at 11.22 on Wednesday. The firm’s market capitalization is $253.01 million. The company has a 50-day moving average price of $10.96 and a 200 day moving average price of $14.40. Esperion Therapeutics has a 1-year low of $9.58 and a 1-year high of $49.36.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.16. During the same period in the previous year, the company posted ($0.55) EPS. Analysts expect that Esperion Therapeutics will post ($3.37) earnings per share for the current fiscal year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.